Navigation Links
SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Date:5/3/2010

SAN FRANCISCO, May 3 /PRNewswire/ -- SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca). The study results were presented at the Dry Eye Summit meeting on April 30th in Fort Lauderdale, Florida, immediately prior to ARVO 2010, the annual meeting of the Association for Research in Vision and Ophthalmology. The study results demonstrated clear improvements in both signs and symptoms of dry eye at 12 weeks. SAR 1118 was well-tolerated, with no serious ocular adverse events reported.  

"We are very pleased with the results of the Phase 2 study," said Charles Semba, MD, chief medical officer of SARcode. "We met our goals of showing improvements in both corneal staining and patient symptoms. We were encouraged too that SAR 1118 achieved these results within 12 weeks, suggesting that it might provide more rapid relief than currently available therapies."

About the Phase 2 Study

The study was a randomized, multicenter, double-masked study comparing SAR 1118 (0.1, 1.0, 5.0%) to placebo. A total of 230 subjects were randomized 1:1:1:1 to receive drops twice daily for 12 weeks. The primary objective measure was inferior corneal staining. The major secondary measures were Ocular Surface Disease Index (OSDI) symptom score and tear production by Schirmer tear test (STT).  

About Dry Eye

Dry eye (keratoconjunctivitis sicca) is a multifactorial disease of the tears and the ocular surface that results in symptoms of discomfort, visual disturbance and tear film instability with the potential to damage the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface (Dry Eye Work Shop (DEWS, 2007)).  According to the DEWS report, approximately 5 million patients, 50 years and older, have moderate to severe dry eye. A major contributing factor towards the development of dry eye is T-cell infiltration, proliferation and inflammatory cytokine production in diseased ocular tissues that leads to reduction in tear film quality and ocular surface inflammation. LFA-1 regulates T-cell adhesion, migration, proliferation, and cytokine production and represents a target for therapeutic intervention.

About SAR 1118

SAR 1118 is a potent novel small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; alpha L beta 2) antagonist that can be targeted against a broad range of ocular inflammatory conditions including dry eye, uveitis, and diabetic macular edema. LFA-1 is member of the integrin family of adhesion receptors found on the surface of all leukocytes and represents a therapeutic target of the immune system central to a number of inflammatory stimuli, whether mediated by cytokines, prostaglandins, leukotrienes or complement. SAR 1118 has demonstrated significant potency in in vitro models in inhibiting cell adhesion, cytokine production, and cellular proliferation.

About SARcode Corporation

SARcode is a venture-backed biopharmaceutical company focused on the development of best in class small molecule LFA-1 antagonists as novel nonsteroidal immunomodulators/anti-inflammatory agents for the treatment of T-cell mediated inflammatory diseases. Institutional investors include Alta Partners and Clarus Venture Partners.

For contact information, visit www.sarcode.com


'/>"/>
SOURCE SARcode Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
2. United Therapeutics Corporation To Announce First Quarter 2010 Financial Results Before Market Open on Thursday, April 29, 2010
3. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
4. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
5. Providence Service Corporation Releases Fourth Quarter and Year End 2009 Results
6. CVS Caremark Corporation Announces Quarterly Dividend
7. ASPEX Corporation is Shifting the Identity of SEMs
8. PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract
9. CSE Corporation Imposes Recall on SR-100 for Evaluation
10. Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date
11. Somanetics Corporation To Release First Quarter 2010 Financial Results and Host Conference Call March 17, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)...  Centurion Medical Products, a leader in medical product innovation and ... removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of a ... pain while preventing unneeded emergency department admission due to severe fecal ...
(Date:7/11/2017)... Zymo Research Corp., also known as ,The Epigenetics Company, announced today the ... precise manner using the myDNAge ™ test. Based on Horvath,s Clock, ... genetics and biostatistics at the David Geffen School of Medicine at ... proprietary DNAge ™ technology is used to analyze DNA methylation patterns ... ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... development of oral drug delivery systems, announced today that ... to schedule an End-of-Phase II meeting with Oramed for ... insulin capsule ORMD-0801 in the treatment of type 2 ... endpoints by indicating a statistically significant lowering of glucose ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and athletic trainers ... say researchers presenting their work at the American Orthopaedic Society for Sports ... evaluating the patterns of change in concussion symptom presentation, diagnostic tools used and ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid ... cancer that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens ... reoccurrence and relapse. With such a challenging diagnosis that requires immediate action, ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
(Date:7/20/2017)... ... 2017 , ... Doctors on Liens, the leading network of medical providers working ... by Dr. Russell Horine, DC to their exclusive list of medical professionals. Horine Chiropractic ... serving as the clinic director and his son Dr. Lee Horine and daughter-in-law Dr. ...
(Date:7/20/2017)... ... July 20, 2017 , ... Using CDRH’s Medical Device Quality ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          , Device makers have ... known as the “CY2016 Annual FDA Medical Device Quality System Data” report. CDRH ...
Breaking Medicine News(10 mins):